Antivirals Linked to Lower Hospitalization in Influenza - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Antivirals Linked to Lower Hospitalization in Influenza

Matched cohort study in nonhospitalized patients

  • By

  • Kathryn Wighton

  • April 13, 2026

  • 3 min

Share

Clinical Scorecard: Antivirals Linked to Lower Hospitalization in Influenza

At a Glance

CategoryDetail
ConditionInfluenza
Key MechanismsAntiviral treatment reduces hospitalization, ICU admission, and mortality rates.
Target PopulationNonhospitalized patients with laboratory-confirmed influenza.
Care SettingMulticenter retrospective cohort study using electronic health records.

Key Highlights

  • Antiviral treatment within 2 days of diagnosis linked to lower hospitalization rates.
  • Hospitalization rates: 1.54% in treated vs 1.70% in untreated patients.
  • Significant reductions in emergency department visits and ICU admissions.
  • Oseltamivir showed consistent benefits across outcomes.
  • Subgroup analysis indicated lower risks in adults and pediatric patients.

Guideline-Based Recommendations

Diagnosis

  • Laboratory confirmation of influenza is essential before treatment.

Management

  • Initiate antiviral therapy within 2 days of diagnosis for optimal outcomes.

Monitoring & Follow-up

  • Assess hospitalization and ICU admission rates post-treatment.

Risks

  • Consider potential unmeasured confounding and limitations in data.

Patient & Prescribing Data

Nonhospitalized patients aged 2 to 64 years without high-risk comorbidities.

Oseltamivir and baloxavir are effective; other antivirals showed no significant benefits.

Clinical Best Practices

  • Administer antivirals promptly within 2 days of influenza diagnosis.
  • Monitor for potential complications and hospitalization post-treatment.
  • Consider patient age and comorbidities when prescribing antivirals.

Related Resources & Content

Original Source(s)

Antivirals Linked to Lower Hospitalization in Influenza

  • by Kathryn Wighton

  • April 13, 2026

Related Content

Multiplex assay improves species-specific parasite diagnosis

"These data provide a new framework for clinically useful parasite-specific serology that helps to direct targeted therapeutic options." 

PrEP surfing common among MSM

Reliance on partners’ PrEP use was more common among younger men and those who had used PrEP in the previous 6 months.

Can LAI-CAB Sustain Long-Term PrEP Use?

A national claims analysis found modest uptake and declining persistence over 2 years despite increasing use of injectable HIV pre-exposure prophylaxis.